COMMUNIQUÉS West-GlobeNewswire

twiist™ Automated Insulin Delivery System is Now Cleared for Adults with Type 2 Diabetes
16/10/2026
Clearance expands twiist's precise insulin delivery and personalized automation to the largest population of people treated with insulin, with time-in-range improvements seen in as little as one day in a pivotal trial 1 [...]
Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy
16/10/2026
Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, [...]
hear.com Receives 2026 Global Recognition Award for Hearing Care Innovation
16/10/2026
Recognition honors hear.com’s Clinic-in-a-Box® teleaudiology platform and Horizon IX hearing aids for expanding access to personalized, medical-grade hearing care MIAMI, Oct. 16, 2026 (GLOBE NEWSWIRE) -- hear.com, an [...]
Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
16/10/2026
BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule [...]
Biomerica Reports First Quarter Fiscal 2027 Financial Results
16/10/2026
InFoods® IBS Commercial Progress: Medicare-related test orders increased 120% in September 2026 compared to August, with growing physician participation and repeat ordering activity InFoods® IBS update: 100% of all [...]
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
16/10/2026
Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human [...]
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
16/10/2026
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Senturi Pharma announces exclusive European distribution agreement for PERTZYE®
16/10/2026
STOCKHOLM, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Senturi Pharma AB and Digestive Care, Inc. today announced the signing of an exclusive distribution agreement concerning PERTZYE ® (pancrelipase) in Europe. Under the [...]
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
16/10/2026
Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer NANJING, China , Oct. 16, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887. [...]
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
16/10/2026
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, [...]
IBA et Framatome s’associent pour industrialiser la production d’Astate-211 au service des thérapies contre le cancer
16/10/2026
Louvain-la-Neuve, Belgique, et Paris, France, le 16 octobre 2026, 8h00 – IBA (Ion Beam Applications, EURONEXT), leader mondial des technologies d'accélérateurs de particules et des solutions de production en médecine [...]
IBA and Framatome join forces to industrialize Astatine-211 production for cancer therapies
16/10/2026
Louvain-la-Neuve, Belgium, and Paris, France, 16 October 2026, 8:00 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, [...]
Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology
16/10/2026
BEIJING, Oct. 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies [...]
City Therapeutics Announces Pricing of Upsized Initial Public Offering
16/10/2026
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi [...]
Avance Clinical to Showcase its Early Phase Center of Excellence Model at AusBiotech International 2026
15/10/2026
Australian-headquartered global CRO with more than 30 years of early phase experience to meet sponsors at Stand #72, Gold Coast, 21–23 October 2026 ADELAIDE, Australia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Avance Clinical [...]
Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
15/10/2026
Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution [...]
MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
15/10/2026
IRVINE, CA – October 15, 2026 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from [...]
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
15/10/2026
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses [...]
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
15/10/2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib), the [...]

Pages